Thu, 10/07/2021 | News

Moderna COVID-19 vaccine dose 1 safety data now available

Moderna COVID-19 vaccine (Spikevax) dose 1 safety data collected as part of the AusVaxSafety national COVID-19 vaccine safety surveillance program has now been published.

AusVaxSafety has received more than 2,200 completed day 3 safety surveys from individuals who received dose 1 of the Moderna COVID-19 vaccine and to date, the data analysis has not detected any safety signals.

The Moderna COVID-19 vaccine is an mRNA vaccine, like the Pfizer COVID-19 vaccine (Comirnaty), and the short-term adverse event profile reported following dose 1 of both these vaccines is extremely similar. 

The most commonly reported side effects following dose 1 of the Moderna COVID-19 vaccine include local reaction (pain at injection site, swelling, redness and itching), fatigue and headache. These common adverse events are associated with the immune response following immunisation, are expected to occur and are generally mild and short-lived, with the majority of recipients recovering within 3 days.

The rates of adverse events and medical attendance reported after dose 1 of Moderna COVID-19 vaccination were very similar to those reported after dose 1 of Pfizer COVID-19 vaccination.  

The addition of Moderna COVID-19 vaccine safety data to the AusVaxSafety website builds on the ongoing surveillance of the Pfizer and AstraZeneca COVID-19 vaccines, providing the public with information on what to expect following vaccination for all COVID-19 vaccines in use in Australia.

As Moderna COVID-19 vaccination only commenced on Monday 20 September 2021 and the minimum recommended dose interval is 4 weeks, only dose 1 data are currently available. These data will be updated weekly and dose 2 data will be added when available.

Access the latest Moderna COVID-19 vaccine safety data here

Photo by Mufid Majnun on Unsplash

Share this article: